Drug Trial Radar · NCT07007962
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Oct 24, 2025
Primary completion
Nov 5, 2027
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jun 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multinational, open label, single arm study that will evaluate the impact of early multi-immune modulation with rilzabrutinib in adult ITP patients who failed first-line treatment. The study includes a screening period (up to 8 weeks), a primary analysis period (up to 28 weeks), a long-term extension period for selected participants (28 weeks) and a 24-week follow-up period only for eligible participants.
Conditions
- Immune Thrombocytopenia
Interventions
rilzabrutinibDrug
Pharmaceutical form:Tablet-Route of administration:Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Durable platelet responseTime frame: Until Week 28
Locations
54 sites in 10 countries. Site status is shown where the registry gives one.
Community Health Partners (CHP) - Community Medical Oncology Specialists (University Oncology Associates) Site Number: 8400005
Clovis, California · Recruiting
University of Southern California (USC) Norris Comprehensive Cancer Center Site Number: 8400015
Los Angeles, California · Recruiting
The Lundquist Institute for Biomedical Innovation - Harbor-UCLA Medical Center Site Number: 8400017
Torrance, California · Recruiting
MedStar Georgetown University Hospital Site Number: 8400014
Washington D.C., District of Columbia · Recruiting
Bleeding and Clotting Disorders Institute Site Number: 8400018
Peoria, Illinois · Recruiting
Tulane University Health Sciences Center - Tulane Avenue-Investigational Site Number: 8400011
New Orleans, Louisiana · Recruiting
Massachusetts General Hospital Site Number: 8400004
Boston, Massachusetts · Recruiting
Beth Israel Deaconess Medical Center Site Number: 8400019
Boston, Massachusetts · Recruiting
Mass General/North Shore Cancer Center Site Number: 8400020
Danvers, Massachusetts · Recruiting
University of Michigan Health - Michigan Medicine - University Hospital Site Number: 8400001
Ann Arbor, Michigan · Recruiting
M Health Center for Bleeding and Clotting Disorders Site Number: 8400013
Minneapolis, Minnesota · Recruiting
Mayo Clinic_Investigational Site Number: 8400009
Rochester, Minnesota · Recruiting
New York Oncology Hematology Site Number: 8400010
Albany, New York · Recruiting
Montefiore Medical Center-Investigational Site Number: 8400012
The Bronx, New York · Recruiting
Oregon Health & Science University - Knight Cancer Institute Site Number: 8400006
Portland, Oregon · Recruiting
East Carolina University Site Number: 8400003
Greenville, South Carolina · Recruiting
Community Cancer Trials of Utah Site Number: 8400002
Ogden, Utah · Recruiting
University of Washington Site Number: 8400008
Seattle, Washington · Recruiting
Investigational Site Number : 0400001
Hanusch-Krankenhaus, Austria · Recruiting
Investigational Site Number : 2030001
Ostrava, Czechia · Recruiting
Investigational Site Number : 2030002
Prague, Czechia · Recruiting
Investigational Site Number : 2500005
Antony, France · Recruiting
Investigational Site Number : 2500003
Créteil, France · Recruiting
Investigational Site Number : 2500001
Dijon, France · Recruiting
Investigational Site Number : 2500002
Pessac, France · Recruiting
Investigational Site Number : 2500004
Toulouse, France · Recruiting
Investigational Site Number : 2760005
Berlin, Germany · Recruiting
Investigational Site Number : 2760001
Dresden, Germany · Recruiting
Investigational Site Number : 2760006
Essen, Germany · Recruiting
Investigational Site Number : 2760002
Frankfurt am Main, Germany · Recruiting
Investigational Site Number : 2760004
Leipzig, Germany · Recruiting
Investigational Site Number : 3480001
Budapest, Hungary · Recruiting
Investigational Site Number : 3480003
Debrecen, Hungary · Recruiting
Investigational Site Number : 3480002
Kaposvár, Hungary · Recruiting
Investigational Site Number : 3800002
Meldola, Italy · Recruiting
Investigational Site Number : 3800004
Milan, Italy · Recruiting
Investigational Site Number : 3800006
Naples, Italy · Recruiting
Investigational Site Number : 3800007
Torino, Italy · Recruiting
Investigational Site Number : 3800001
Trieste, Italy · Recruiting
Investigational Site Number : 3800003
Vicenza, Italy · Recruiting
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.